David A. Siegel Liminal Bio Sciences Inc. Transaction History

Two Sigma Advisers, LP

  • $43.8 Billion
  • Q2 2024

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2022

May 16, 2022
BUY
$0.82 - $1.13 $8,856 - $12,203
10,800 New
10,800 $11,000

Others Institutions Holding LMNL

# of Institutions
2
Shares Held
234
Call Options Held
0
Put Options Held
0
View Full List

About Liminal BioSciences Inc.

LMNL Quotes by TradingView
  • Ticker LMNL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 31,042,600
  • Description
  • Liminal BioSciences Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel small molecule drug therapeutics for inflammatory, fibrotic, and metabolic diseases in Canada and the United Kingdom. The company's lead product candidate is fezagepras (PBI-4050), which has been completed Phase I clinical trial for the trea...
More about LMNL
Track David A. Siegel's Portfolio

Track David A. Siegel Portfolio

Follow David A. Siegel (Two Sigma Advisers, LP) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email